Switch theme
Sign up to access all valuation multiples
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
2005
59
LTM Revenue $1.0M
LTM EBITDA -$67.3M
$334M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
aTyr Pharma has a last 12-month revenue (LTM) of $1.0M and a last 12-month EBITDA of -$67.3M.
In the most recent fiscal year, aTyr Pharma achieved revenue of $0.2M and an EBITDA of -$66.4M.
aTyr Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See aTyr Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.0M | XXX | $0.2M | XXX | XXX | XXX |
| Gross Profit | $1.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$67.3M | XXX | -$66.4M | XXX | XXX | XXX |
| EBITDA Margin | -6908% | XXX | -28244% | XXX | XXX | XXX |
| EBIT | -$66.5M | XXX | -$67.9M | XXX | XXX | XXX |
| EBIT Margin | -6824% | XXX | -28900% | XXX | XXX | XXX |
| Net Profit | -$62.5M | XXX | -$64.0M | XXX | XXX | XXX |
| Net Margin | -6409% | XXX | -27244% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, aTyr Pharma's stock price is $4.
aTyr Pharma has current market cap of $398M, and EV of $334M.
See aTyr Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $334M | $398M | XXX | XXX | XXX | XXX | $-0.78 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, aTyr Pharma has market cap of $398M and EV of $334M.
aTyr Pharma's trades at 1423.4x EV/Revenue multiple, and -5.0x EV/EBITDA.
Equity research analysts estimate aTyr Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
aTyr Pharma has a P/E ratio of -6.4x.
See valuation multiples for aTyr Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $398M | XXX | $398M | XXX | XXX | XXX |
| EV (current) | $334M | XXX | $334M | XXX | XXX | XXX |
| EV/Revenue | 343.1x | XXX | 1423.4x | XXX | XXX | XXX |
| EV/EBITDA | -5.0x | XXX | -5.0x | XXX | XXX | XXX |
| EV/EBIT | -5.0x | XXX | -4.9x | XXX | XXX | XXX |
| EV/Gross Profit | 343.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -6.4x | XXX | -6.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -4.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialaTyr Pharma's last 12 month revenue growth is 1196%
aTyr Pharma's revenue per employee in the last FY averaged $4K, while opex per employee averaged $1.2M for the same period.
aTyr Pharma's rule of 40 is -13586% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
aTyr Pharma's rule of X is -3919% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for aTyr Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1196% | XXX | 985% | XXX | XXX | XXX |
| EBITDA Margin | -6908% | XXX | -28244% | XXX | XXX | XXX |
| EBITDA Growth | 0% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -13586% | XXX | -27049% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -3919% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $4K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 23137% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 29000% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
aTyr Pharma acquired XXX companies to date.
Last acquisition by aTyr Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . aTyr Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was aTyr Pharma founded? | aTyr Pharma was founded in 2005. |
| Where is aTyr Pharma headquartered? | aTyr Pharma is headquartered in United States of America. |
| How many employees does aTyr Pharma have? | As of today, aTyr Pharma has 59 employees. |
| Who is the CEO of aTyr Pharma? | aTyr Pharma's CEO is Dr. Sanjay S. Shukla, M.D.,M.S.. |
| Is aTyr Pharma publicy listed? | Yes, aTyr Pharma is a public company listed on NAS. |
| What is the stock symbol of aTyr Pharma? | aTyr Pharma trades under ATYR ticker. |
| When did aTyr Pharma go public? | aTyr Pharma went public in 2015. |
| Who are competitors of aTyr Pharma? | Similar companies to aTyr Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of aTyr Pharma? | aTyr Pharma's current market cap is $398M |
| What is the current revenue of aTyr Pharma? | aTyr Pharma's last 12 months revenue is $1.0M. |
| What is the current revenue growth of aTyr Pharma? | aTyr Pharma revenue growth (NTM/LTM) is 1196%. |
| What is the current EV/Revenue multiple of aTyr Pharma? | Current revenue multiple of aTyr Pharma is 343.1x. |
| Is aTyr Pharma profitable? | Yes, aTyr Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of aTyr Pharma? | aTyr Pharma's last 12 months EBITDA is -$67.3M. |
| What is aTyr Pharma's EBITDA margin? | aTyr Pharma's last 12 months EBITDA margin is -6908%. |
| What is the current EV/EBITDA multiple of aTyr Pharma? | Current EBITDA multiple of aTyr Pharma is -5.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
